On February 3, 2021, Treatment Action Group, Médecins du Monde, hepCoalition, and the UNITE network presented a virtual policy dialogue among policymakers, global civil society organizations, and community leaders who share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts. Following the International AIDS Society COVID-19 Prevention Conference, the virtual policy dialogue launches a policy brief that highlights how R&D and investments used for HCV have benefitted the COVID-19 response. We invite policymakers and community leaders to share their expertise, experiences on the ground, and initiatives that have sustained HCV responses during the pandemic.
Joelle Dountio, Treatment Action Group, and Samantha Hodgetts, Médecins du Monde
Bryn Gay – Treatment Action Group
Mariam Jashi – Member of Parliament; chairperson of the Education, Science and Culture Committee, and member of the Health and Social Affair Committees (Georgia)
Ketho Angami – ARK Foundation (India)
Ibtissame Azzaoui – Member of Parliament (Morocco)
Andrew Scheibe – TB HIV Care and University of Pretoria